293 related articles for article (PubMed ID: 23321955)
1. Childhood varicella-zoster virus vaccination in Belgium: cost-effective only in the long run or without exogenous boosting?
Bilcke J; van Hoek AJ; Beutels P
Hum Vaccin Immunother; 2013 Apr; 9(4):812-22. PubMed ID: 23321955
[TBL] [Abstract][Full Text] [Related]
2. Cost-effectiveness of varicella and herpes zoster vaccination in Sweden: An economic evaluation using a dynamic transmission model.
Wolff E; Widgren K; Scalia Tomba G; Roth A; Lep T; Andersson S
PLoS One; 2021; 16(5):e0251644. PubMed ID: 33984060
[TBL] [Abstract][Full Text] [Related]
3. The cost-effectiveness of varicella and combined varicella and herpes zoster vaccination programmes in the United Kingdom.
van Hoek AJ; Melegaro A; Gay N; Bilcke J; Edmunds WJ
Vaccine; 2012 Feb; 30(6):1225-34. PubMed ID: 22119592
[TBL] [Abstract][Full Text] [Related]
4. Distribution of Health Effects and Cost-effectiveness of Varicella Vaccination are Shaped by the Impact on Herpes Zoster.
van Lier A; Lugnér A; Opstelten W; Jochemsen P; Wallinga J; Schellevis F; Sanders E; de Melker H; van Boven M
EBioMedicine; 2015 Oct; 2(10):1494-9. PubMed ID: 26629544
[TBL] [Abstract][Full Text] [Related]
5. Varicella vaccination in England and Wales: cost-utility analysis.
Brisson M; Edmunds WJ
Arch Dis Child; 2003 Oct; 88(10):862-9. PubMed ID: 14500303
[TBL] [Abstract][Full Text] [Related]
6. Vaccination to prevent varicella: Goldman and King's response to Myers' interpretation of Varicella Active Surveillance Project data.
Goldman GS; King PG
Hum Exp Toxicol; 2014 Aug; 33(8):886-93. PubMed ID: 24275643
[TBL] [Abstract][Full Text] [Related]
7. An economic evaluation and incremental analysis of the cost effectiveness of three universal childhood varicella vaccination strategies for Ireland.
Ahern S; Browne J; Murphy A; Teljeur C; Ryan M
Vaccine; 2024 May; 42(14):3321-3332. PubMed ID: 38609807
[TBL] [Abstract][Full Text] [Related]
8. Review of the United States universal varicella vaccination program: Herpes zoster incidence rates, cost-effectiveness, and vaccine efficacy based primarily on the Antelope Valley Varicella Active Surveillance Project data.
Goldman GS; King PG
Vaccine; 2013 Mar; 31(13):1680-94. PubMed ID: 22659447
[TBL] [Abstract][Full Text] [Related]
9. Systematic review of models assessing the economic value of routine varicella and herpes zoster vaccination in high-income countries.
Damm O; Ultsch B; Horn J; Mikolajczyk RT; Greiner W; Wichmann O
BMC Public Health; 2015 Jun; 15():533. PubMed ID: 26041469
[TBL] [Abstract][Full Text] [Related]
10. Modelling the impact of a combined varicella and zoster vaccination programme on the epidemiology of varicella zoster virus in England.
van Hoek AJ; Melegaro A; Zagheni E; Edmunds WJ; Gay N
Vaccine; 2011 Mar; 29(13):2411-20. PubMed ID: 21277405
[TBL] [Abstract][Full Text] [Related]
11. Cost-effectiveness of routine varicella vaccination using the measles, mumps, rubella and varicella vaccine in France: an economic analysis based on a dynamic transmission model for varicella and herpes zoster.
Littlewood KJ; Ouwens MJ; Sauboin C; Tehard B; Alain S; Denis F
Clin Ther; 2015 Apr; 37(4):830-841.e7. PubMed ID: 25721380
[TBL] [Abstract][Full Text] [Related]
12. Current and future effects of varicella and herpes zoster vaccination in Germany - Insights from a mathematical model in a country with universal varicella vaccination.
Horn J; Karch A; Damm O; Kretzschmar ME; Siedler A; Ultsch B; Weidemann F; Wichmann O; Hengel H; Greiner W; Mikolajczyk RT
Hum Vaccin Immunother; 2016 Jul; 12(7):1766-76. PubMed ID: 26835890
[TBL] [Abstract][Full Text] [Related]
13. The impact of 2-dose routine measles, mumps, rubella, and varicella vaccination in France on the epidemiology of varicella and zoster using a dynamic model with an empirical contact matrix.
Ouwens MJ; Littlewood KJ; Sauboin C; Téhard B; Denis F; Boëlle PY; Alain S
Clin Ther; 2015 Apr; 37(4):816-829.e10. PubMed ID: 25726457
[TBL] [Abstract][Full Text] [Related]
14. Cost-effectiveness analysis of universal varicella vaccination in Turkey using a dynamic transmission model.
Wolfson LJ; Daniels VJ; Pillsbury M; Kurugöl Z; Yardimci C; Kyle J; Dinleyici EC
PLoS One; 2019; 14(8):e0220921. PubMed ID: 31408505
[TBL] [Abstract][Full Text] [Related]
15. What We Know Now: An Economic Evaluation of Chickenpox Vaccination and Dose Timing Using an Agent-Based Model.
Rafferty ERS; McDonald W; Osgood ND; Doroshenko A; Farag M
Value Health; 2021 Jan; 24(1):50-60. PubMed ID: 33431153
[TBL] [Abstract][Full Text] [Related]
16. Universal varicella vaccination: efficacy trends and effect on herpes zoster.
Goldman GS
Int J Toxicol; 2005; 24(4):205-13. PubMed ID: 16126614
[TBL] [Abstract][Full Text] [Related]
17. The cost-effectiveness of varicella vaccination in Canada.
Brisson M; Edmunds WJ
Vaccine; 2002 Jan; 20(7-8):1113-25. PubMed ID: 11803072
[TBL] [Abstract][Full Text] [Related]
18. Modelling the impact of varicella vaccination on varicella and zoster.
Karhunen M; Leino T; Salo H; Davidkin I; Kilpi T; Auranen K
Epidemiol Infect; 2010 Apr; 138(4):469-81. PubMed ID: 19796447
[TBL] [Abstract][Full Text] [Related]
19. The impact of demographic changes, exogenous boosting and new vaccination policies on varicella and herpes zoster in Italy: a modelling and cost-effectiveness study.
Melegaro A; Marziano V; Del Fava E; Poletti P; Tirani M; Rizzo C; Merler S
BMC Med; 2018 Jul; 16(1):117. PubMed ID: 30012132
[TBL] [Abstract][Full Text] [Related]
20. Modeling the impact of combined vaccination programs against varicella and herpes zoster in Norway.
Marchetti S; Guzzetta G; Flem E; Mirinaviciute G; Scalia Tomba G; Manfredi P
Vaccine; 2018 Feb; 36(8):1116-1125. PubMed ID: 29366704
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
